drugset
drugset / Trial / NCT03441529

A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants

NCT03441529 ↗

Phase 1 Completed 18 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelOther

Summary

The main purpose of this study is to evaluate the effect of intravenous (IV) infusions of piperacillin/tazobactam on the pharmacokinetics (PK) of JNJ-63549109 after a single oral dose of lumicitabine in healthy adult participants.

Timeline

Start
2018-02-09
Primary completion
2018-05-03
Completion
2018-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumicitabine Small molecule 1000 mg Oral
Subject Piperacillin Small molecule 4 g Intravenous
Subject Tazobactam Small molecule 0.5 g Intravenous

Indications

No indication recorded.